These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 2139830)

  • 21. [Analysis of the distribution of class I HLA-antigens in patients with systemic scleroderma with regard to features of the clinical course of the disease and therapy with D-penicillamine].
    Pevnitskiĭ LA; Guseva NG; Sibiriakova LG; Oskilko TG
    Genetika; 1989 Jun; 25(6):1101-7. PubMed ID: 2806895
    [TBL] [Abstract][Full Text] [Related]  

  • 22. D-penicillamine treatment of progressive systemic sclerosis (scleroderma): a comparison of clinical and in vitro effects.
    Shapiro LS; Prince RK; Buckingham RB; Rodnan GP
    J Rheumatol; 1983 Apr; 10(2):316-8. PubMed ID: 6864687
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Minimal changes nephrotic syndrome associated to penicillamine treatment].
    Basterrechea MA; de Arriba G; García-Martín F; Sánchez-Heras M; Giménez-Vega E; Sánchez J
    Nefrologia; 2004; 24(2):183-7. PubMed ID: 15219094
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Scleroderma and thyroid diseases].
    Mourier-Clavreul MC; Rousset H; Claudy A
    Ann Dermatol Venereol; 1989; 116(10):701-6. PubMed ID: 2692498
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Penicillamine for scleroderma.
    Fulghum DD; Katz R
    Arch Dermatol; 1968 Jul; 98(1):51-2. PubMed ID: 5241672
    [No Abstract]   [Full Text] [Related]  

  • 26. [Effect of penicillin and D-penicillamine on beta-galactosidase activity in patients with progressive scleroderma].
    Schulze E; Herrmann K; Haustein UF; Krusche U; Rothenburger I
    Dermatol Monatsschr; 1988; 174(11):661-6. PubMed ID: 3145222
    [No Abstract]   [Full Text] [Related]  

  • 27. Penicillamine for systemic sclerosis?
    Drug Ther Bull; 1974 Sep; 12(19):75-6. PubMed ID: 4469492
    [No Abstract]   [Full Text] [Related]  

  • 28. [D-penicillamine therapy of chronic polyarthritis].
    Günther R; Gabl F; Knapp E
    Z Rheumaforsch; 1973; 32(7):313-25. PubMed ID: 4741805
    [No Abstract]   [Full Text] [Related]  

  • 29. Unilateral ptosis as an initial manifestation of D-penicillamine induced myasthenia gravis.
    Raynauld JP; Lee YS; Kornfeld P; Fries JF
    J Rheumatol; 1993 Sep; 20(9):1592-3. PubMed ID: 8164222
    [TBL] [Abstract][Full Text] [Related]  

  • 30. D-penicillamine-induced crescentic glomerulonephritis in a patient with scleroderma.
    García-Porrúa C; González-Gay MA; Bouza P
    Nephron; 2000 Jan; 84(1):101-2. PubMed ID: 10644924
    [No Abstract]   [Full Text] [Related]  

  • 31. Monoclonal gammopathy penicillamine-induced polymyositis and systemic sclerosis.
    Nishikai M; Funatsu Y; Homma M
    Arch Dermatol; 1974 Aug; 110(2):253-5. PubMed ID: 4853253
    [No Abstract]   [Full Text] [Related]  

  • 32. [Basic therapy of rheumatoid arthritis with D-penicillamine. Personal contribution and critical observations].
    Gigante D; Teodori S; Crispo M
    Fortschr Med; 1983 Apr; 101(13):613-8. PubMed ID: 6852728
    [No Abstract]   [Full Text] [Related]  

  • 33. [Penicillamine in the treatment of patients with systemic scleroderma].
    Gandzha IM
    Vrach Delo; 1987 May; (5):66-7. PubMed ID: 3617690
    [No Abstract]   [Full Text] [Related]  

  • 34. [Long-term use of D-penicillamine in systemic scleroderma and rheumatoid arthritis].
    Guseva NG; Trofimova TM; Oskilko TG; Panasiuk AF; Tarasenkova TA
    Klin Med (Mosk); 1986 Jun; 64(6):44-50. PubMed ID: 3747436
    [No Abstract]   [Full Text] [Related]  

  • 35. [Penicillamine in the treatment of scleroderma. Lathyrogenic drugs].
    Szczepanski A
    Przegl Dermatol; 1971; 58(3):355-9. PubMed ID: 4944035
    [No Abstract]   [Full Text] [Related]  

  • 36. Zinc and zinc-dependent enzymes in penicillamine-treated patients with generalized scleroderma.
    Jepsen LV; Eggert J
    Acta Derm Venereol; 1984; 64(5):424-7. PubMed ID: 6208723
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial.
    Clements PJ; Furst DE; Wong WK; Mayes M; White B; Wigley F; Weisman MH; Barr W; Moreland LW; Medsger TA; Steen V; Martin RW; Collier D; Weinstein A; Lally E; Varga J; Weiner S; Andrews B; Abeles M; Seibold JR
    Arthritis Rheum; 1999 Jun; 42(6):1194-203. PubMed ID: 10366112
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Ultrastructural comparative study of the behavior of collagen tissue and elastic tissue during 3 pathological states (Marfans disease, scleroderma due to vitamin K-1 lathyrogenic effect of penicillamine)].
    Gauthier Y; Surlève-Bazeille JE; Gauthier O; Texier L
    Ann Dermatol Syphiligr (Paris); 1973; 100(5-6):525-9. PubMed ID: 4802994
    [No Abstract]   [Full Text] [Related]  

  • 39. Penicillamine-induced polymyositis.
    Leden I; Libelius R
    Scand J Rheumatol; 1985; 14(1):90-3. PubMed ID: 4001884
    [No Abstract]   [Full Text] [Related]  

  • 40. Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial.
    DeMarco PJ; Weisman MH; Seibold JR; Furst DE; Wong WK; Hurwitz EL; Mayes M; White B; Wigley F; Barr W; Moreland L; Medsger TA; Steen V; Martin RW; Collier D; Weinstein A; Lally E; Varga J; Weiner SR; Andrews B; Abeles M; Clements PJ
    Arthritis Rheum; 2002 Nov; 46(11):2983-9. PubMed ID: 12428241
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.